EGFR and head and neck squamous cell carcinoma: Interestingly, when we compare the drug response data of unselected HNSCC versus that of NSCLC with or without the actionable mutations, HNSCC sensitivity towards osimertinib was comparable with that of EGFR-mutated NSCLC (P = 0.4180), and also significantly more sensitive than EGFR-wildtype NSCLC (P < 0.0001) [Fig. 4A].